Toxicologic and carcinogenic effects of the type IV phosphodiesterase inhibitor RP 73401 on the nasal olfactory tissue in rats.
RP 73401, a type IV phosphodiesterase inhibitor, caused toxic effects in the nasal olfactory region of Sprague-Dawley rats when administered by either oral or inhalation exposure. A single oral administration of RP 73401 (at a dose of > or = 50 mg/kg) or 5-day inhalation exposure (1 hr/day) at a dose of approximately 1.0 mg/kg per day caused degeneration and sloughing of the olfactory surface epithelium. Degeneration and loss of Bowman's glands were noted in the underlying lamina propria and submucosa. Electron microscopy of these lesions demonstrated that sustentacular cells and the epithelial cells lining Bowman's glands were the primary target cells in the olfactory mucosa. The earliest ultrastructural changes detected in these cells were dilatation and vesiculation of the endoplasmic reticulum, suggesting that metabolic activation is important for the toxic effects. In repeated-dose studies, 13 wk of oral dosing at 2.0 or 6.0 mg/kg per day resulted in subtle disorganization of the olfactory epithelium, whereas basal cell hyperplasia in the olfactory epithelium was identified in a 6-month inhalation study at a dose of 1.0 mg/kg per day. A 2-yr inhalation carcinogenicity study resulted in tumors of the nasal olfactory region in rats treated at 0.5 and 1.0 mg/kg per day. Most tumors were classified as olfactory neuroblastomas, and immunohistochemistry on selected tumors was consistent with their being of neuroectodermal origin. Of the species studied (rat, mouse, and dog), the olfactory toxicity of RP 73401 was confined to the rat, and the toxicity was likely related to metabolic activation by olfactory epithelial cells rather than the phosphodiesterase activity of the compound.
Pino
M V
MV
Rhône-Poulenc Rorer Research and Development, Collegeville, Pennsylvania 19426, USA.
Valerio
M G
MG
Miller
G K
GK
Larson
J L
JL
Rosolia
D L
DL
Jayyosi
Z
Z
Crouch
C N
CN
Trojanowski
J Q
JQ
Geiger
L E
LE
D000280:Administration, Inhalation; D000284:Administration, Oral; D000818:Animals; D001549:Benzamides / Q000633:toxicity*; D015197:Carcinogenicity Tests; D005260:Female; D005904:Glial Fibrillary Acidic Protein / Q000032:analysis; D007150:Immunohistochemistry; D007381:Intermediate Filament Proteins / Q000032:analysis; D007633:Keratins / Q000032:analysis; D008297:Male; D009296:Nasal Cavity / Q000187:drug effects* / Q000473:pathology / Q000648:ultrastructure; D009297:Nasal Mucosa / Q000187:drug effects* / Q000473:pathology / Q000648:ultrastructure; D009419:Nerve Tissue Proteins; D064231:Nestin; D010726:Phosphodiesterase Inhibitors / Q000633:toxicity*; D011725:Pyridines / Q000633:toxicity*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors
D001549:Benzamides; D005904:Glial Fibrillary Acidic Protein; D007381:Intermediate Filament Proteins; D009419:Nerve Tissue Proteins; C577485:Nes protein, mouse; C577486:Nes protein, rat; D064231:Nestin; D010726:Phosphodiesterase Inhibitors; D011725:Pyridines; D007633:Keratins; C087566:piclamilast